Application of Mass Spectrometry in Pancreatic Cancer Translational Research

Peng Ge; Yalan Luo; Haiyang Chen; Jiayue Liu; Haoya Guo; Caiming Xu; Jialin Qu; Guixin Zhang; Hailong Chen

doi:10.3389/fonc.2021.667427

Application of Mass Spectrometry in Pancreatic Cancer Translational Research

Front Oncol. 2021 Oct 11:11:667427. doi: 10.3389/fonc.2021.667427. eCollection 2021.

Authors

Peng Ge^{1

2

3}, Yalan Luo^{1

2}, Haiyang Chen^{1

2

3}, Jiayue Liu^{1

2

3}, Haoya Guo^{1

2

3}, Caiming Xu¹, Jialin Qu^{2

3}, Guixin Zhang^{1

2}, Hailong Chen^{1

2}

Affiliations

¹ Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
² Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, China.
³ Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Abstract

Pancreatic cancer (PC) is one of the most common malignant tumors in the digestive tract worldwide, with increased morbidity and mortality. In recent years, with the development of surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy, and the change of the medical thinking model, remarkable progress has been made in researching comprehensive diagnosis and treatment of PC. However, the present situation of diagnostic and treatment of PC is still unsatisfactory. There is an urgent need for academia to fully integrate the basic research and clinical data from PC to form a research model conducive to clinical translation and promote the proper treatment of PC. This paper summarized the translation progress of mass spectrometry (MS) in the pathogenesis, diagnosis, prognosis, and PC treatment to promote the basic research results of PC into clinical diagnosis and treatment.

Keywords: diagnosis; mass spectrometry; pancreatic cancer; therapy; translational science.

Publication types

Review